The use of dendritic cells (DCs) for tumor immunotherapy represents a powerful approach
for harnessing the patient's own immune system to eliminate tumor cells. However …

The US Food and Drug Administration's approval of the first cell‐based immunotherapy has
rejuvenated interest in the field. Early clinical trials have established the ability of dendritic …

Since their discovery, there has been significant progress in the understanding of dendritic
cell (DC) biology. Their capacity for priming an immune response against pathogens and …

Importance of the field: Dendritic cells (DC) are a clear choice for use in cancer
immunotherapy, and much research has focused on generating DC for clinical use …

Cancer immunotherapy aims at eliciting an immune response directed against tumor
antigens to help fight off residual tumor cells and thereby improve survival and quality of life …

Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …

Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in
animal models and humans have led to their exploitation as anticancer vaccines. Although …

Dendritic cells are professional antigen-presenting cells with a key role in both immunity
induction and tolerance maintenance. Dendritic cells are highly specialized in antigen …

Cancer immunotherapy attempts to harness the power and specificity of the immune system
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …

Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit.
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …